Suppr超能文献

异基因造血干细胞移植前的减低强度预处理:移植后早期需要T细胞以诱导移植物抗淋巴瘤效应。

Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect.

作者信息

Glass B, Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G, Trümper L, Schmitz N

机构信息

Universtitätsklinikum Göttingen, Robert Koch Strasse 40, Göttingen, Germany.

出版信息

Bone Marrow Transplant. 2004 Sep;34(5):391-7. doi: 10.1038/sj.bmt.1704600.

Abstract

In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P=0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL.

摘要

在侵袭性淋巴瘤预后不良的复发患者中,由于肿瘤的快速生长,减低强度预处理后行异基因外周血干细胞移植(PBSCT)可能存在局限性。我们试图通过中等强度预处理后行异基因干细胞移植(SCT)来解决这一问题。共有21例患者在异基因SCT前接受了氟达拉滨、白消安和环磷酰胺治疗。前10例患者采用通过选择移植物中的CD34+进行移植物抗宿主病(GVHD)预防(I组)。接下来的11例患者接受未处理的移植物以及霉酚酸酯加环孢素A(II组)。I组未观察到GVHD。相比之下,II组患者有发生急性GVHD(aGVHD)的显著风险(6例患者发生II-IV级急性GVHD)。然而,I组所有存活患者在9个月内病情进展。相比之下,II组9例存活患者中有8例在中位观察时间10.5个月(范围为4-2个月)后仍处于缓解状态。两组间生存率差异显著(P=0.004)。多变量分析确定强化GVHD预防是生存的重要危险因素。这些结果支持在侵袭性淋巴瘤中存在临床相关的移植物抗淋巴瘤(GVL)效应。对于预后不良的侵袭性非霍奇金淋巴瘤(NHL)患者,不建议对移植物进行T细胞去除(或CD34选择)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验